JP2021073256A - セミカルバジド感受性アミンオキシダーゼ(ssao)の阻害剤の医薬的塩形態 - Google Patents
セミカルバジド感受性アミンオキシダーゼ(ssao)の阻害剤の医薬的塩形態 Download PDFInfo
- Publication number
- JP2021073256A JP2021073256A JP2021012044A JP2021012044A JP2021073256A JP 2021073256 A JP2021073256 A JP 2021073256A JP 2021012044 A JP2021012044 A JP 2021012044A JP 2021012044 A JP2021012044 A JP 2021012044A JP 2021073256 A JP2021073256 A JP 2021073256A
- Authority
- JP
- Japan
- Prior art keywords
- disease
- compound according
- purity
- tetrahydro
- isopropyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000003839 salts Chemical group 0.000 title abstract description 22
- 102100027159 Membrane primary amine oxidase Human genes 0.000 title abstract description 12
- 239000003112 inhibitor Substances 0.000 title abstract description 10
- 108010028700 Amine Oxidase (Copper-Containing) Proteins 0.000 title description 4
- 150000004677 hydrates Chemical class 0.000 claims abstract 2
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Substances C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 claims description 39
- 150000001875 compounds Chemical class 0.000 claims description 34
- 201000010099 disease Diseases 0.000 claims description 18
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 18
- 208000027866 inflammatory disease Diseases 0.000 claims description 15
- 239000000203 mixture Substances 0.000 claims description 15
- 230000004054 inflammatory process Effects 0.000 claims description 13
- 238000000034 method Methods 0.000 claims description 13
- 206010061218 Inflammation Diseases 0.000 claims description 12
- 230000002757 inflammatory effect Effects 0.000 claims description 9
- 230000005764 inhibitory process Effects 0.000 claims description 9
- 208000023275 Autoimmune disease Diseases 0.000 claims description 7
- 206010047115 Vasculitis Diseases 0.000 claims description 6
- 208000026278 immune system disease Diseases 0.000 claims description 6
- 201000006417 multiple sclerosis Diseases 0.000 claims description 6
- 239000008194 pharmaceutical composition Substances 0.000 claims description 6
- 208000024827 Alzheimer disease Diseases 0.000 claims description 5
- 201000004810 Vascular dementia Diseases 0.000 claims description 5
- 208000019425 cirrhosis of liver Diseases 0.000 claims description 5
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 5
- JHGGOTFKWARTGB-UHFFFAOYSA-N CS(=O)(=O)O.C(C1=CN=CC=C1)(=O)O Chemical compound CS(=O)(=O)O.C(C1=CN=CC=C1)(=O)O JHGGOTFKWARTGB-UHFFFAOYSA-N 0.000 claims description 4
- 201000004681 Psoriasis Diseases 0.000 claims description 4
- 208000006011 Stroke Diseases 0.000 claims description 4
- 206010003246 arthritis Diseases 0.000 claims description 4
- 206010009887 colitis Diseases 0.000 claims description 4
- FSSOYPTUNGNSQS-UHFFFAOYSA-N pyridine-3-carboxylic acid;sulfuric acid Chemical compound [H+].[O-]S([O-])(=O)=O.OC(=O)C1=CC=C[NH+]=C1 FSSOYPTUNGNSQS-UHFFFAOYSA-N 0.000 claims description 4
- 206010007559 Cardiac failure congestive Diseases 0.000 claims description 3
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims description 3
- 206010019280 Heart failures Diseases 0.000 claims description 3
- 208000018737 Parkinson disease Diseases 0.000 claims description 3
- 239000003795 chemical substances by application Substances 0.000 claims description 3
- 206010012601 diabetes mellitus Diseases 0.000 claims description 3
- 206010015037 epilepsy Diseases 0.000 claims description 3
- 208000028867 ischemia Diseases 0.000 claims description 3
- 210000004185 liver Anatomy 0.000 claims description 3
- 201000008482 osteoarthritis Diseases 0.000 claims description 3
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 3
- 230000004614 tumor growth Effects 0.000 claims description 3
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 claims description 2
- 208000022309 Alcoholic Liver disease Diseases 0.000 claims description 2
- 201000001320 Atherosclerosis Diseases 0.000 claims description 2
- 206010003827 Autoimmune hepatitis Diseases 0.000 claims description 2
- 206010007558 Cardiac failure chronic Diseases 0.000 claims description 2
- 208000021910 Cerebral Arterial disease Diseases 0.000 claims description 2
- 208000005145 Cerebral amyloid angiopathy Diseases 0.000 claims description 2
- 206010008609 Cholangitis sclerosing Diseases 0.000 claims description 2
- 206010009900 Colitis ulcerative Diseases 0.000 claims description 2
- 208000011231 Crohn disease Diseases 0.000 claims description 2
- 206010012438 Dermatitis atopic Diseases 0.000 claims description 2
- 206010012442 Dermatitis contact Diseases 0.000 claims description 2
- 206010012689 Diabetic retinopathy Diseases 0.000 claims description 2
- 201000009794 Idiopathic Pulmonary Fibrosis Diseases 0.000 claims description 2
- 208000003456 Juvenile Arthritis Diseases 0.000 claims description 2
- 206010059176 Juvenile idiopathic arthritis Diseases 0.000 claims description 2
- 208000009525 Myocarditis Diseases 0.000 claims description 2
- 206010063837 Reperfusion injury Diseases 0.000 claims description 2
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 claims description 2
- 206010040047 Sepsis Diseases 0.000 claims description 2
- 201000009594 Systemic Scleroderma Diseases 0.000 claims description 2
- 206010042953 Systemic sclerosis Diseases 0.000 claims description 2
- 201000006704 Ulcerative Colitis Diseases 0.000 claims description 2
- 208000006673 asthma Diseases 0.000 claims description 2
- 201000008937 atopic dermatitis Diseases 0.000 claims description 2
- 208000018093 autoimmune cholangitis Diseases 0.000 claims description 2
- 230000009787 cardiac fibrosis Effects 0.000 claims description 2
- 206010008118 cerebral infarction Diseases 0.000 claims description 2
- 208000019069 chronic childhood arthritis Diseases 0.000 claims description 2
- 208000010247 contact dermatitis Diseases 0.000 claims description 2
- 230000007850 degeneration Effects 0.000 claims description 2
- 208000036971 interstitial lung disease 2 Diseases 0.000 claims description 2
- 230000000968 intestinal effect Effects 0.000 claims description 2
- 208000002551 irritable bowel syndrome Diseases 0.000 claims description 2
- 201000002215 juvenile rheumatoid arthritis Diseases 0.000 claims description 2
- 230000000938 luteal effect Effects 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 230000002685 pulmonary effect Effects 0.000 claims description 2
- 208000010157 sclerosing cholangitis Diseases 0.000 claims description 2
- 208000017520 skin disease Diseases 0.000 claims description 2
- 208000011580 syndromic disease Diseases 0.000 claims description 2
- 201000004595 synovitis Diseases 0.000 claims description 2
- 230000009885 systemic effect Effects 0.000 claims description 2
- 208000008439 Biliary Liver Cirrhosis Diseases 0.000 claims 1
- 208000033222 Biliary cirrhosis primary Diseases 0.000 claims 1
- 206010019668 Hepatic fibrosis Diseases 0.000 claims 1
- 208000012654 Primary biliary cholangitis Diseases 0.000 claims 1
- 201000001263 Psoriatic Arthritis Diseases 0.000 claims 1
- 208000036824 Psoriatic arthropathy Diseases 0.000 claims 1
- 230000003176 fibrotic effect Effects 0.000 claims 1
- 208000012947 ischemia reperfusion injury Diseases 0.000 claims 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 abstract description 19
- 101710132836 Membrane primary amine oxidase Proteins 0.000 abstract description 11
- 239000003814 drug Substances 0.000 abstract description 10
- 150000003467 sulfuric acid derivatives Chemical class 0.000 abstract description 5
- AMIPLQUGEQTRSM-GWCFXTLKSA-N [(3s)-oxolan-3-yl] (4s)-4-propan-2-yl-1,4,6,7-tetrahydroimidazo[4,5-c]pyridine-5-carboxylate Chemical compound N1([C@H](C=2N=CNC=2CC1)C(C)C)C(=O)O[C@H]1CCOC1 AMIPLQUGEQTRSM-GWCFXTLKSA-N 0.000 abstract description 2
- RTJWNAARWPQVSL-VVBGOIRUSA-N S(C)(=O)(=O)O.C(C)(C)[C@@H]1N(CCC2=C1N=CN2)C(=O)O[C@@H]2COCC2 Chemical class S(C)(=O)(=O)O.C(C)(C)[C@@H]1N(CCC2=C1N=CN2)C(=O)O[C@@H]2COCC2 RTJWNAARWPQVSL-VVBGOIRUSA-N 0.000 abstract 1
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 30
- 239000000523 sample Substances 0.000 description 29
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 21
- 239000000243 solution Substances 0.000 description 16
- 238000004128 high performance liquid chromatography Methods 0.000 description 15
- 239000012458 free base Substances 0.000 description 12
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 12
- 238000005259 measurement Methods 0.000 description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 11
- 239000007787 solid Substances 0.000 description 10
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 9
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 9
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 9
- 230000000694 effects Effects 0.000 description 9
- 230000008018 melting Effects 0.000 description 9
- 238000002844 melting Methods 0.000 description 9
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 8
- JVTAAEKCZFNVCJ-REOHCLBHSA-N L-lactic acid Chemical compound C[C@H](O)C(O)=O JVTAAEKCZFNVCJ-REOHCLBHSA-N 0.000 description 8
- 229920001971 elastomer Polymers 0.000 description 8
- 238000002474 experimental method Methods 0.000 description 8
- 238000000634 powder X-ray diffraction Methods 0.000 description 8
- 239000005060 rubber Substances 0.000 description 8
- 239000002904 solvent Substances 0.000 description 8
- 238000004458 analytical method Methods 0.000 description 7
- 230000008901 benefit Effects 0.000 description 7
- 229940079593 drug Drugs 0.000 description 7
- 238000009472 formulation Methods 0.000 description 7
- 238000010438 heat treatment Methods 0.000 description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 6
- 230000015572 biosynthetic process Effects 0.000 description 6
- 238000004296 chiral HPLC Methods 0.000 description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- 238000000113 differential scanning calorimetry Methods 0.000 description 6
- 230000006870 function Effects 0.000 description 6
- 238000004255 ion exchange chromatography Methods 0.000 description 6
- 239000011541 reaction mixture Substances 0.000 description 6
- 238000001179 sorption measurement Methods 0.000 description 6
- 238000002411 thermogravimetry Methods 0.000 description 6
- DTQVDTLACAAQTR-UHFFFAOYSA-N trifluoroacetic acid Substances OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 6
- 102000004190 Enzymes Human genes 0.000 description 5
- 108090000790 Enzymes Proteins 0.000 description 5
- 238000005481 NMR spectroscopy Methods 0.000 description 5
- 239000007864 aqueous solution Substances 0.000 description 5
- 239000011521 glass Substances 0.000 description 5
- 230000014759 maintenance of location Effects 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 230000002265 prevention Effects 0.000 description 5
- 102000016893 Amine Oxidase (Copper-Containing) Human genes 0.000 description 4
- 206010016654 Fibrosis Diseases 0.000 description 4
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 4
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 4
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 4
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 4
- 229910019142 PO4 Inorganic materials 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- WNLRTRBMVRJNCN-UHFFFAOYSA-N adipic acid Chemical compound OC(=O)CCCCC(O)=O WNLRTRBMVRJNCN-UHFFFAOYSA-N 0.000 description 4
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 4
- 239000000872 buffer Substances 0.000 description 4
- 238000013480 data collection Methods 0.000 description 4
- 230000004761 fibrosis Effects 0.000 description 4
- 238000001914 filtration Methods 0.000 description 4
- 229910052739 hydrogen Inorganic materials 0.000 description 4
- 210000000265 leukocyte Anatomy 0.000 description 4
- 229910052757 nitrogen Inorganic materials 0.000 description 4
- 235000021317 phosphate Nutrition 0.000 description 4
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 4
- AOJFQRQNPXYVLM-UHFFFAOYSA-N pyridin-1-ium;chloride Chemical compound [Cl-].C1=CC=[NH+]C=C1 AOJFQRQNPXYVLM-UHFFFAOYSA-N 0.000 description 4
- 239000000377 silicon dioxide Substances 0.000 description 4
- 239000003826 tablet Substances 0.000 description 4
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 4
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 3
- 206010028980 Neoplasm Diseases 0.000 description 3
- 206010035664 Pneumonia Diseases 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 239000013543 active substance Substances 0.000 description 3
- VZTDIZULWFCMLS-UHFFFAOYSA-N ammonium formate Chemical compound [NH4+].[O-]C=O VZTDIZULWFCMLS-UHFFFAOYSA-N 0.000 description 3
- 239000012296 anti-solvent Substances 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 239000013078 crystal Substances 0.000 description 3
- 238000002425 crystallisation Methods 0.000 description 3
- 230000008025 crystallization Effects 0.000 description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N dichloromethane Natural products ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- 230000007613 environmental effect Effects 0.000 description 3
- 235000019439 ethyl acetate Nutrition 0.000 description 3
- ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 description 3
- 238000000227 grinding Methods 0.000 description 3
- 230000012010 growth Effects 0.000 description 3
- IBTWUVRCFHJPKN-UHFFFAOYSA-N hydron;pyridine-3-carboxylic acid;chloride Chemical compound Cl.OC(=O)C1=CC=CN=C1 IBTWUVRCFHJPKN-UHFFFAOYSA-N 0.000 description 3
- 230000036039 immunity Effects 0.000 description 3
- 230000028709 inflammatory response Effects 0.000 description 3
- 238000012423 maintenance Methods 0.000 description 3
- 201000001441 melanoma Diseases 0.000 description 3
- 230000001537 neural effect Effects 0.000 description 3
- 239000003921 oil Substances 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- 238000001907 polarising light microscopy Methods 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- WYURNTSHIVDZCO-UHFFFAOYSA-N tetrahydrofuran Substances C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- XDPCNPCKDGQBAN-BYPYZUCNSA-N (3s)-oxolan-3-ol Chemical compound O[C@H]1CCOC1 XDPCNPCKDGQBAN-BYPYZUCNSA-N 0.000 description 2
- MJVNWJUAUPLDGK-VIFPVBQESA-N (4s)-4-propan-2-yl-1,4,6,7-tetrahydroimidazo[4,5-c]pyridine-5-carboxylic acid Chemical compound CC(C)[C@@H]1N(C(O)=O)CCC2=C1N=CN2 MJVNWJUAUPLDGK-VIFPVBQESA-N 0.000 description 2
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
- 239000005711 Benzoic acid Substances 0.000 description 2
- 201000003883 Cystic fibrosis Diseases 0.000 description 2
- 229930182843 D-Lactic acid Natural products 0.000 description 2
- CKLJMWTZIZZHCS-UHFFFAOYSA-N D-OH-Asp Natural products OC(=O)C(N)CC(O)=O CKLJMWTZIZZHCS-UHFFFAOYSA-N 0.000 description 2
- RGHNJXZEOKUKBD-SQOUGZDYSA-N D-gluconic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 2
- RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Natural products OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 description 2
- JVTAAEKCZFNVCJ-UWTATZPHSA-N D-lactic acid Chemical compound C[C@@H](O)C(O)=O JVTAAEKCZFNVCJ-UWTATZPHSA-N 0.000 description 2
- 208000002249 Diabetes Complications Diseases 0.000 description 2
- 206010012655 Diabetic complications Diseases 0.000 description 2
- 102100027988 GTP-binding protein Rhes Human genes 0.000 description 2
- 101000578396 Homo sapiens GTP-binding protein Rhes Proteins 0.000 description 2
- AMIMRNSIRUDHCM-UHFFFAOYSA-N Isopropylaldehyde Chemical compound CC(C)C=O AMIMRNSIRUDHCM-UHFFFAOYSA-N 0.000 description 2
- CKLJMWTZIZZHCS-UWTATZPHSA-N L-Aspartic acid Natural products OC(=O)[C@H](N)CC(O)=O CKLJMWTZIZZHCS-UWTATZPHSA-N 0.000 description 2
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 2
- FEWJPZIEWOKRBE-JCYAYHJZSA-L L-tartrate(2-) Chemical compound [O-]C(=O)[C@H](O)[C@@H](O)C([O-])=O FEWJPZIEWOKRBE-JCYAYHJZSA-L 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 2
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 2
- 235000011054 acetic acid Nutrition 0.000 description 2
- 239000001361 adipic acid Substances 0.000 description 2
- 235000011037 adipic acid Nutrition 0.000 description 2
- 150000001299 aldehydes Chemical class 0.000 description 2
- 229910052782 aluminium Inorganic materials 0.000 description 2
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 2
- 229960005261 aspartic acid Drugs 0.000 description 2
- 230000001363 autoimmune Effects 0.000 description 2
- 239000002585 base Substances 0.000 description 2
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 2
- 229940092714 benzenesulfonic acid Drugs 0.000 description 2
- 235000010233 benzoic acid Nutrition 0.000 description 2
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 108010062049 chirobiotic T Proteins 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 229910052593 corundum Inorganic materials 0.000 description 2
- 239000010431 corundum Substances 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 201000002491 encephalomyelitis Diseases 0.000 description 2
- AFAXGSQYZLGZPG-UHFFFAOYSA-N ethanedisulfonic acid Chemical compound OS(=O)(=O)CCS(O)(=O)=O AFAXGSQYZLGZPG-UHFFFAOYSA-N 0.000 description 2
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 2
- 239000011888 foil Substances 0.000 description 2
- 239000001530 fumaric acid Substances 0.000 description 2
- 235000012208 gluconic acid Nutrition 0.000 description 2
- 229950006191 gluconic acid Drugs 0.000 description 2
- 229960002989 glutamic acid Drugs 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 229920001903 high density polyethylene Polymers 0.000 description 2
- 239000004700 high-density polyethylene Substances 0.000 description 2
- 150000003840 hydrochlorides Chemical class 0.000 description 2
- 210000002865 immune cell Anatomy 0.000 description 2
- 230000008595 infiltration Effects 0.000 description 2
- 238000001764 infiltration Methods 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 150000002500 ions Chemical class 0.000 description 2
- JMMWKPVZQRWMSS-UHFFFAOYSA-N isopropyl acetate Chemical compound CC(C)OC(C)=O JMMWKPVZQRWMSS-UHFFFAOYSA-N 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 2
- 239000011976 maleic acid Substances 0.000 description 2
- 229940098895 maleic acid Drugs 0.000 description 2
- 230000035800 maturation Effects 0.000 description 2
- 229940098779 methanesulfonic acid Drugs 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- UXOUKMQIEVGVLY-UHFFFAOYSA-N morin Natural products OC1=CC(O)=CC(C2=C(C(=O)C3=C(O)C=C(O)C=C3O2)O)=C1 UXOUKMQIEVGVLY-UHFFFAOYSA-N 0.000 description 2
- 125000000636 p-nitrophenyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)[N+]([O-])=O 0.000 description 2
- 230000036961 partial effect Effects 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 2
- 229910052697 platinum Inorganic materials 0.000 description 2
- 230000010287 polarization Effects 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 238000004007 reversed phase HPLC Methods 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 229910052710 silicon Inorganic materials 0.000 description 2
- 239000010703 silicon Substances 0.000 description 2
- 150000003384 small molecules Chemical class 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 238000013268 sustained release Methods 0.000 description 2
- 239000012730 sustained-release form Substances 0.000 description 2
- 238000004448 titration Methods 0.000 description 2
- 239000003643 water by type Substances 0.000 description 2
- NXLNNXIXOYSCMB-UHFFFAOYSA-N (4-nitrophenyl) carbonochloridate Chemical compound [O-][N+](=O)C1=CC=C(OC(Cl)=O)C=C1 NXLNNXIXOYSCMB-UHFFFAOYSA-N 0.000 description 1
- GBCOKAPEXMLZDU-FVGYRXGTSA-N (4S)-4-propan-2-yl-1,4,6,7-tetrahydroimidazo[4,5-c]pyridine-5-carboxylic acid sulfuric acid Chemical class OS(O)(=O)=O.CC(C)[C@@H]1N(CCc2[nH]cnc12)C(O)=O GBCOKAPEXMLZDU-FVGYRXGTSA-N 0.000 description 1
- SJHPCNCNNSSLPL-CSKARUKUSA-N (4e)-4-(ethoxymethylidene)-2-phenyl-1,3-oxazol-5-one Chemical compound O1C(=O)C(=C/OCC)\N=C1C1=CC=CC=C1 SJHPCNCNNSSLPL-CSKARUKUSA-N 0.000 description 1
- 238000005160 1H NMR spectroscopy Methods 0.000 description 1
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 1
- KKADPXVIOXHVKN-UHFFFAOYSA-N 4-hydroxyphenylpyruvic acid Chemical compound OC(=O)C(=O)CC1=CC=C(O)C=C1 KKADPXVIOXHVKN-UHFFFAOYSA-N 0.000 description 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 1
- 229910000809 Alumel Inorganic materials 0.000 description 1
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 1
- 239000005695 Ammonium acetate Substances 0.000 description 1
- OJQDVKRXYOZHRR-UHFFFAOYSA-N CC(C)C1NCCc2c1[nH]cn2 Chemical compound CC(C)C1NCCc2c1[nH]cn2 OJQDVKRXYOZHRR-UHFFFAOYSA-N 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 102000019034 Chemokines Human genes 0.000 description 1
- 108010012236 Chemokines Proteins 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 108030000926 Diamine oxidases Proteins 0.000 description 1
- ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 1
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 1
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 1
- 208000009386 Experimental Arthritis Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 102000058061 Glucose Transporter Type 4 Human genes 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 238000003109 Karl Fischer titration Methods 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- -1 Pyridine-5-carboxylate sulfate hydrate Chemical compound 0.000 description 1
- 108091006300 SLC2A4 Proteins 0.000 description 1
- 208000032005 Spinocerebellar ataxia with axonal neuropathy type 2 Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 210000001789 adipocyte Anatomy 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 235000019257 ammonium acetate Nutrition 0.000 description 1
- 229940043376 ammonium acetate Drugs 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 238000005349 anion exchange Methods 0.000 description 1
- 238000005571 anion exchange chromatography Methods 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 230000001772 anti-angiogenic effect Effects 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 229910052786 argon Inorganic materials 0.000 description 1
- 208000033361 autosomal recessive with axonal neuropathy 2 spinocerebellar ataxia Diseases 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000009134 cell regulation Effects 0.000 description 1
- 230000005754 cellular signaling Effects 0.000 description 1
- 150000001793 charged compounds Chemical class 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 229940075614 colloidal silicon dioxide Drugs 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 239000006059 cover glass Substances 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- DEZRYPDIMOWBDS-UHFFFAOYSA-N dcm dichloromethane Chemical compound ClCCl.ClCCl DEZRYPDIMOWBDS-UHFFFAOYSA-N 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 239000002274 desiccant Substances 0.000 description 1
- 238000003795 desorption Methods 0.000 description 1
- 235000019700 dicalcium phosphate Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 108010037444 diisopropylglutathione ester Proteins 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 210000003989 endothelium vascular Anatomy 0.000 description 1
- 239000002158 endotoxin Substances 0.000 description 1
- OJCSPXHYDFONPU-UHFFFAOYSA-N etoac etoac Chemical compound CCOC(C)=O.CCOC(C)=O OJCSPXHYDFONPU-UHFFFAOYSA-N 0.000 description 1
- 230000000763 evoking effect Effects 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 238000003818 flash chromatography Methods 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 230000009477 glass transition Effects 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 208000014829 head and neck neoplasm Diseases 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000004896 high resolution mass spectrometry Methods 0.000 description 1
- PPZMYIBUHIPZOS-UHFFFAOYSA-N histamine dihydrochloride Chemical compound Cl.Cl.NCCC1=CN=CN1 PPZMYIBUHIPZOS-UHFFFAOYSA-N 0.000 description 1
- 229960004931 histamine dihydrochloride Drugs 0.000 description 1
- SBHVDHKJXXFHQL-UHFFFAOYSA-N imidazo[4,5-c]pyridine-5-carboxylic acid Chemical compound OC(=O)N1C=CC2=NC=NC2=C1 SBHVDHKJXXFHQL-UHFFFAOYSA-N 0.000 description 1
- 238000007654 immersion Methods 0.000 description 1
- 229910052738 indium Inorganic materials 0.000 description 1
- APFVFJFRJDLVQX-UHFFFAOYSA-N indium atom Chemical compound [In] APFVFJFRJDLVQX-UHFFFAOYSA-N 0.000 description 1
- 230000004968 inflammatory condition Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 229960001375 lactose Drugs 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 239000012669 liquid formulation Substances 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 229920001684 low density polyethylene Polymers 0.000 description 1
- 239000004702 low-density polyethylene Substances 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 238000001819 mass spectrum Methods 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 229940126601 medicinal product Drugs 0.000 description 1
- COTNUBDHGSIOTA-UHFFFAOYSA-N meoh methanol Chemical compound OC.OC COTNUBDHGSIOTA-UHFFFAOYSA-N 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 238000003801 milling Methods 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- YGAMIEYKXHAVBP-UHFFFAOYSA-N molecular hydrogen;hydrochloride Chemical compound Cl.[H][H] YGAMIEYKXHAVBP-UHFFFAOYSA-N 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 210000002464 muscle smooth vascular Anatomy 0.000 description 1
- 229910052759 nickel Inorganic materials 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229960004838 phosphoric acid Drugs 0.000 description 1
- FIYYJQQFRVGGAM-UHFFFAOYSA-N phosphoric acid;pyridine-3-carboxylic acid Chemical compound OP(O)(O)=O.OC(=O)C1=CC=CN=C1 FIYYJQQFRVGGAM-UHFFFAOYSA-N 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 235000020004 porter Nutrition 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- OVARTBFNCCXQKS-UHFFFAOYSA-N propan-2-one;hydrate Chemical compound O.CC(C)=O OVARTBFNCCXQKS-UHFFFAOYSA-N 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 208000005069 pulmonary fibrosis Diseases 0.000 description 1
- 238000010926 purge Methods 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 238000011552 rat model Methods 0.000 description 1
- 230000007115 recruitment Effects 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000013214 routine measurement Methods 0.000 description 1
- 229910052594 sapphire Inorganic materials 0.000 description 1
- 239000010980 sapphire Substances 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 229940079832 sodium starch glycolate Drugs 0.000 description 1
- 229920003109 sodium starch glycolate Polymers 0.000 description 1
- 239000008109 sodium starch glycolate Substances 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 239000012086 standard solution Substances 0.000 description 1
- 229940032147 starch Drugs 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- WHRNULOCNSKMGB-UHFFFAOYSA-N tetrahydrofuran thf Chemical class C1CCOC1.C1CCOC1 WHRNULOCNSKMGB-UHFFFAOYSA-N 0.000 description 1
- WROMPOXWARCANT-UHFFFAOYSA-N tfa trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.OC(=O)C(F)(F)F WROMPOXWARCANT-UHFFFAOYSA-N 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 210000005166 vasculature Anatomy 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Abstract
Description
(3S)−テトラヒドロフラン−3−イル(4S)−4−イソプロピル−1,4,6,7−テトラヒドロ−5H−イミダゾ[4,5−c]ピリジン−5−カルボキシレートホスフェート;
(3S)−テトラヒドロフラン−3−イル(4S)−4−イソプロピル−1,4,6,7−テトラヒドロ−5H−イミダゾ[4,5−c]ピリジン−5−カルボキシレートサルフェート水和物;及び
(3S)−テトラヒドロフラン−3−イル(4S)−4−イソプロピル−1,4,6,7−テトラヒドロ−5H−イミダゾ[4,5−c]ピリジン−5−カルボキシレートメシレート
を発見した。
本明細書で用いられる「治療」は、名前が付けられている疾患若しくは病状の予防、またはいったん確立された前記疾患の改善若しくは除去を含む。
組成物
塩形成実験
適切な場合には、モノおよびヘミ塩の両方を形成させるために、24個の酸性対イオン(表1参照)を用いて塩スクリーニングを行った。様々な範囲の溶媒系および条件を用いて、9セットの実験を行った。
(3S)−テトラヒドロフラン−3−イル(4S)−4−イソプロピル−1,4,6,7−テトラヒドロ−5H−イミダゾ[4,5−c]ピリジン−5−カルボキシレート遊離塩基(20mg)の別々のサンプルを、IPA(2.5容量)、アセトン−水(9:1 v/v、2.5容量)またはDIPE(10容量)に溶解した。溶液を40℃に加熱し、各試験酸(1または0.5当量、表1参照)を穏やかに撹拌しながら添加した。バイアルを40℃で1時間保持し、次いで1℃/分で5℃まで冷却した。混合物を5℃で一晩保持した。得られた全ての固体を濾過により収集し、XRPDにより分析した。油およびゴムは、結晶化を助けるために各温度で4時間、RT〜50℃の成熟サイクルに供した。溶液を周囲条件で蒸発させた。残留物を1H−NMRおよびDSCによって分析して、加熱時の塩形成および/または潜在的な結晶化を評価した。
(3S)−テトラヒドロフラン−3−イル(4S)−4−イソプロピル−1,4,6,7−テトラヒドロ−5H−イミダゾ[4,5−c]ピリジン−5−カルボキシレート遊離塩基(15mg)の別々のサンプルをIPAc(3%v/vの水有り及び無し;5容量)に溶解し、溶液を40℃に加熱した。穏やかに撹拌しながら、対応する酸(1または0.5当量、表1参照)を添加した。バイアルを40℃で1時間保持し、次いで溶液が濁るまで漸増量の抗−溶媒(n−ヘプタンまたはTBME)を添加した。この時点で、全てのサンプルを1℃/分で5℃まで冷却し、5℃で一晩保持した。沈殿が生じていない場合には、より多くの抗−溶媒が添加された。得られた全ての固体を濾過により収集し、XRPDにより分析した。油およびゴムは、結晶化を助けるために各温度で4時間、RT〜50℃の成熟サイクルに供した。溶液を周囲温度より低い温度まで冷却し、沈殿が生じなければ蒸発させた。
核磁気共鳴(NMR)
液体クロマトグラフィー−質量分析(LCMS)
示差走査熱量分析(DSC)
熱重量分析(TGA)
偏光顕微鏡観察(PLM)
加熱ステージ顕微鏡観察(HSM)[融点]
HPLCによる化学的純度測定
カールフィッシャー滴定(KF)による水分測定
重量法蒸気吸着測定(GVS)
イオンクロマトグラフィー(IC)
結果
Aq 水性
DCM ジクロロメタン
DIPEA ジイソピロピルエチルアミン
ee 鏡像体過剰率
ES+ エレクトロスプレー
EtOAc 酢酸エチル
h 時間(単数又は複数)
HPLC 高速液体クロマトグラフィー
HRMS 高分解能質量分析
LCMS 液体クロマトグラフィー−質量分析
M モル
MeOH メタノール
[MH+] プロトン付加分子イオン
min 分
RP 逆相
MS 質量分析
RT 保持時間
sat 飽和した
THF テトラヒドロフラン
TFA トリフルオロ酢酸
実験方法
分析LCMSはAgilent 1100 HPLCシステムに接続したWaters ZQ質量分析計で行った。分析HPLCはAgilent 1100システムで行った。高分解能質量スペクトル(HRMS)はAgilent 1100 HPLCシステムに接続したAgilent MSD-TOFで得た。分析の間、較正は2つの質量でチェックし、必要に応じて自動的に補正した。スペクトルは正イオンエレクトロスプレーモードで収集した。収集質量範囲はm/z100〜1100であった。質量ピークのプロファイル検出を用いた。フラッシュクロマトグラフィーはRediSepシリカカラムを備えたCombiFlash Companionシステム、またはStrata SI-1シリカギガチューブを備えたFlash Master Personalのいずれかで行った。逆相HPLCはPhenomenex Synergi Hydro RP150x10mm、YMC ODS-A100/150x20mmまたはChirobiotic T250x10mmカラムを備えたGilson システム(Gilson 321平衡ポンプ付きGilson 322ポンプ、およびGilson 215オートサンプラー)で行った。逆相カラムクロマトグラフィーはMerck LiChroprep(登録商標)RP-18(40−63μm)シリカカラムを備えたGilsonシステム(Gilson 321ポンプおよびGilson FC204フラクションコレクター)で行った。化合物はACD6.0を用いて自動的に命名した。すべての化合物は真空ポンプ中で一晩乾燥した。
分析HPLCおよびLCMSデータは以下の条件で得た:
キラルHPLCで他は以下の条件で得た:
中間体1
4−イソプロピル−4,5,6,7−テトラヒドロ−1H−イミダゾ[4,5−c]ピリジンハイドロクロライド
分析LCMS:純度>90%(システムA、RT=0.51分)、ES+:166.4[MH]+。
中間体2
4−ニトロフェニル 4−イソプロピル−1,4,6,7−テトラヒドロ−5H−イミダゾ[4,5−c]ピリジン−5−カルボキシレート
(3S)−テトラヒドロフラン−3−イル(4S)−4−イソプロピル−1,4,6,7−テトラヒドロ−5H−イミダゾ[4,5−c]−ピリジン−5−カルボキシレートメシラートは、二重LDPEライナー中に3gアリコートで分配し、ケーブルタイで密封し、乾燥剤パウチをホイルバッグに入れた後、ヒートシールしたときの安定性及び吸湿性についても評価した。次いで、ホイルバッグをHDPE蓋を取り付けたHDPEケグ(keg)に入れた。これらの条件は、典型的なGMPレベルの保存条件に一致する。安定性をHPLCで評価し、吸湿性をカールフィッシャー(KF)滴定によって評価した。(3S)−テトラヒドロフラン−3−イル(4S)−4−イソプロピル−1,4,6,7−テトラヒドロ−5H−イミダゾ[4,5−c]ピリジン−5−カルボキシレートメシレートは、25℃/60%RHで3年間にわたり水を吸収せず、40℃/75%RHで6ヶ月後に僅かに0.1%の水の摂取で、0.1%しか分解されなかった。
Claims (21)
- (3S)−テトラヒドロフラン−3−イル(4S)−4−イソプロピル−1,4,6,7−テトラヒドロ−5H−イミダゾ[4,5−c]ピリジン−5−カルボキシレートメシレート、および
(3S)−テトラヒドロフラン−3−イル(4S)−4−イソプロピル−1,4,6,7−テトラヒドロ−5H−イミダゾ[4,5−c]ピリジン−5−カルボキシレートサルフェート、
およびそれらの水和物、
から選択される、化合物。 - 請求項1に記載の化合物、および1種以上の適切な賦形剤を含む、医薬用組成物。
- 炎症、炎症性疾患、免疫若しくは自己免疫疾患、または腫瘍成長の阻害の治療における、あるいは治療のための薬剤の製造における使用のための請求項1に記載の化合物または請求項2に記載の医薬用組成物。
- 炎症、炎症性疾患、免疫若しくは自己免疫疾患、または腫瘍成長の阻害の治療方法であって、そのような疾患を患っている患者に請求項1に記載の化合物または請求項2に記載の医薬用組成物の有効量を投与することを含む方法。
- 前記炎症、または炎症性疾患、または免疫若しくは自己免疫疾患は、関節炎(関節リウマチ、若年性関節リウマチ、変形性関節炎、乾癬性関節炎を含む)、滑膜炎、血管炎、シェーグレン疾患、腸の炎症と関係している状態(クローン病、潰瘍性大腸炎、炎症性大腸炎および過敏性腸症候群を含む)、アテローム性動脈硬化症、多発性硬化症、アルツハイマー病、血管性認知症、パーキンソン病、脳アミロイド血管症、皮質下梗塞および白質脳症を伴う常染色体優性脳動脈症、肺炎症疾患(ぜんそく、慢性閉塞性肺疾患、および呼吸窮迫症候群を含む)、線維性疾患(特発性肺線維症、心臓線維症、肝線維症、および全身性硬化症(強皮症)を含む)、皮膚の炎症性疾患(接触性皮膚炎、アトピー性皮膚炎、および乾癬を含む)、眼の炎症性疾患(加齢性黄斑変性症、ブドウ膜炎、および糖尿病性網膜症を含む)、全身性炎症反応症候群、敗血症、肝臓の炎症性および/または自己免疫性疾患(自己免疫性肝炎、原発性胆汁性肝硬変、アルコール性肝臓疾患、硬化性胆管炎、および自己免疫性胆管炎を含む)、糖尿病(1型または2型)および/またはその合併症、慢性心不全、鬱血性心不全、虚血症(脳卒中、および虚血−再潅流障害を含む)若しくは心筋梗塞および/またはその合併症、あるいはてんかんである、請求項3に記載の化合物若しくは医薬組成物、または請求項4に記載の方法。
- リウマチ性関節炎、変形性関節炎、肝線維症、慢性閉塞性肺疾患、多発性硬化症、シェーグレン疾患、アルツハイマー病、パーキンソン病、炎症性大腸炎または血管性認知症から選択される疾患の治療のための請求項3に記載の化合物若しくは医薬組成物、または請求項4に記載の方法。
- (3S)−テトラヒドロフラン−3−イル(4S)−4−イソプロピル−1,4,6,7−テトラヒドロ−5H−イミダゾ[4,5−c]ピリジン−5−カルボキシレートメシレートである、請求項1に記載の化合物。
- 95%を超える純度を有する、請求項7に記載の化合物。
- 99%を超える純度を有する、請求項7に記載の化合物。
- 99.5%を超える純度を有する、請求項7に記載の化合物。
- 95%を超えるエナンチオマー純度を有する、請求項7〜10のいずれか1項に記載の化合物。
- 99%を超えるエナンチオマー純度を有する、請求項7〜10のいずれか1項に記載の化合物。
- 99.5%を超えるエナンチオマー純度を有する、請求項7〜10のいずれか1項に記載の化合物。
- (3S)−テトラヒドロフラン−3−イル(4S)−4−イソプロピル−1,4,6,7−テトラヒドロ−5H−イミダゾ[4,5−c]ピリジン−5−カルボキシレートサルフェートおよびその水和物である、請求項1に記載の化合物。
- (3S)−テトラヒドロフラン−3−イル(4S)−4−イソプロピル−1,4,6,7−テトラヒドロ−5H−イミダゾ[4,5−c]ピリジン−5−カルボキシレートサルフェート 1.5H2Oである、請求項14に記載の化合物。
- 95%を超える純度を有する、請求項14または15に記載の化合物。
- 99%を超える純度を有する、請求項14または15に記載の化合物。
- 99.5%を超える純度を有する、請求項14または15に記載の化合物。
- 95%を超えるエナンチオマー純度を有する、請求項14〜18のいずれか1項に記載の化合物。
- 99%を超えるエナンチオマー純度を有する、請求項14〜18のいずれか1項に記載の化合物。
- 99.5%を超えるエナンチオマー純度を有する、請求項14〜18のいずれか1項に記載の化合物。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB1507031.1 | 2015-04-24 | ||
GBGB1507031.1A GB201507031D0 (en) | 2015-04-24 | 2015-04-24 | New pharmaceutical salt forms |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2017555499A Division JP2018513189A (ja) | 2015-04-24 | 2016-04-22 | セミカルバジド感受性アミンオキシダーゼ(ssao)の阻害剤の医薬的塩形態 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2021073256A true JP2021073256A (ja) | 2021-05-13 |
JP2021073256A5 JP2021073256A5 (ja) | 2021-08-12 |
Family
ID=53488629
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2017555499A Pending JP2018513189A (ja) | 2015-04-24 | 2016-04-22 | セミカルバジド感受性アミンオキシダーゼ(ssao)の阻害剤の医薬的塩形態 |
JP2021012044A Pending JP2021073256A (ja) | 2015-04-24 | 2021-01-28 | セミカルバジド感受性アミンオキシダーゼ(ssao)の阻害剤の医薬的塩形態 |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2017555499A Pending JP2018513189A (ja) | 2015-04-24 | 2016-04-22 | セミカルバジド感受性アミンオキシダーゼ(ssao)の阻害剤の医薬的塩形態 |
Country Status (20)
Country | Link |
---|---|
US (1) | US10316034B2 (ja) |
EP (1) | EP3286190B1 (ja) |
JP (2) | JP2018513189A (ja) |
KR (1) | KR20170139045A (ja) |
CN (2) | CN112851669A (ja) |
AR (1) | AR104360A1 (ja) |
AU (1) | AU2016251707B2 (ja) |
BR (1) | BR112017020016A2 (ja) |
CA (1) | CA2979144A1 (ja) |
DK (1) | DK3286190T3 (ja) |
EA (1) | EA035668B1 (ja) |
ES (1) | ES2804155T3 (ja) |
GB (1) | GB201507031D0 (ja) |
HK (1) | HK1249906A1 (ja) |
HU (1) | HUE049985T2 (ja) |
IL (1) | IL254153A0 (ja) |
MX (1) | MX2017013049A (ja) |
PT (1) | PT3286190T (ja) |
SG (1) | SG11201707867WA (ja) |
WO (1) | WO2016170351A1 (ja) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB201507048D0 (en) * | 2015-04-24 | 2015-06-10 | Proximagen Ltd | Treatment of pain |
GB201507036D0 (en) * | 2015-04-24 | 2015-06-10 | Proximagen Ltd | Crystalline enzyme inhibitor compound |
GB201618029D0 (en) | 2016-10-25 | 2016-12-07 | Proximagen Ltd | New process |
CN108017634A (zh) * | 2017-12-15 | 2018-05-11 | 清华大学 | 一种制备吡咯并多环衍生物的方法 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2012506368A (ja) * | 2008-09-16 | 2012-03-15 | プロキシマジェン エルティーディー | 新規化合物i |
Family Cites Families (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4141899A (en) | 1976-01-07 | 1979-02-27 | Societa' Farmaceutici Italia S.P.A. | 4,5,6,7-Tetrahydroimidazo-[4,5-c]-pyridine derivatives |
IT1098015B (it) | 1978-08-07 | 1985-08-31 | Farmaceutici Italia | Nuovi 4,5,6,7,-tetraidroimidazo-aperta par.quadrata 4,5-c chiusa par.quadrata-piridin-derivati |
US6908926B1 (en) | 1999-04-16 | 2005-06-21 | Novo Nordisk A/S | Substituted imidazoles, their preparation and use |
AU3956900A (en) * | 1999-04-16 | 2000-11-02 | Boehringer Ingelheim International Gmbh | Substituted imidazoles, their preparation and use |
WO2002038153A1 (en) | 2000-11-09 | 2002-05-16 | Biovitrum Ab | New use of 4, 5, 6, 7-tetrahydroimidazo-[4,5-c]pyridine derivatives |
SE0004101D0 (sv) | 2000-11-09 | 2000-11-09 | Pharmacia Ab | New use |
KR20060135781A (ko) * | 2004-02-25 | 2006-12-29 | 라 졸라 파마슈티칼 컴파니 | 질병의 치료를 위한 아민 및 아미드 |
US20070066646A1 (en) | 2005-08-02 | 2007-03-22 | Genmedica Therapeutics Sl | Compounds for Inhibiting Copper-Containing Amine Oxidases and Uses Thereof |
EP3042668B1 (en) | 2006-06-07 | 2018-09-19 | The Board of Trustees of the Leland Stanford Junior University | Anti-leukocyte recruitment therapy for the treatment of seizures and epilepsy |
JP5613671B2 (ja) * | 2008-09-16 | 2014-10-29 | プロキシマジェン エルティーディーProximagen Ltd. | 新規化合物ii |
GB201004311D0 (en) * | 2010-03-15 | 2010-04-28 | Proximagen Ltd | New enzyme inhibitor compounds |
IN2014DN01883A (ja) * | 2011-09-14 | 2015-05-15 | Proximagen Ltd | |
GB201115853D0 (en) * | 2011-09-14 | 2011-10-26 | Proximagen Ltd | New enzyme inhibitor compounds |
GB201304526D0 (en) * | 2013-03-13 | 2013-04-24 | Proximagen Ltd | New compounds |
US20160113893A1 (en) | 2013-06-12 | 2016-04-28 | Proximagen Limited | New therapeutic uses of enzyme inhibitors |
ES2714125T3 (es) | 2014-04-15 | 2019-05-27 | Pecsi Tudomanyegyetem | Inhibidores de la amino oxidasa sensible a la semicarbazida para uso como analgésicos en una neuropatía traumática y una inflamación neurogénica |
GB201507036D0 (en) | 2015-04-24 | 2015-06-10 | Proximagen Ltd | Crystalline enzyme inhibitor compound |
GB201507048D0 (en) * | 2015-04-24 | 2015-06-10 | Proximagen Ltd | Treatment of pain |
-
2015
- 2015-04-24 GB GBGB1507031.1A patent/GB201507031D0/en not_active Ceased
-
2016
- 2016-04-22 CA CA2979144A patent/CA2979144A1/en not_active Abandoned
- 2016-04-22 PT PT167198928T patent/PT3286190T/pt unknown
- 2016-04-22 SG SG11201707867WA patent/SG11201707867WA/en unknown
- 2016-04-22 BR BR112017020016A patent/BR112017020016A2/pt not_active IP Right Cessation
- 2016-04-22 MX MX2017013049A patent/MX2017013049A/es unknown
- 2016-04-22 AU AU2016251707A patent/AU2016251707B2/en not_active Ceased
- 2016-04-22 CN CN202110072000.2A patent/CN112851669A/zh active Pending
- 2016-04-22 CN CN201680023326.3A patent/CN107531702A/zh active Pending
- 2016-04-22 ES ES16719892T patent/ES2804155T3/es active Active
- 2016-04-22 KR KR1020177032022A patent/KR20170139045A/ko unknown
- 2016-04-22 EP EP16719892.8A patent/EP3286190B1/en active Active
- 2016-04-22 WO PCT/GB2016/051119 patent/WO2016170351A1/en active Application Filing
- 2016-04-22 DK DK16719892.8T patent/DK3286190T3/da active
- 2016-04-22 AR ARP160101126A patent/AR104360A1/es unknown
- 2016-04-22 HU HUE16719892A patent/HUE049985T2/hu unknown
- 2016-04-22 EA EA201792121A patent/EA035668B1/ru not_active IP Right Cessation
- 2016-04-22 JP JP2017555499A patent/JP2018513189A/ja active Pending
- 2016-04-22 US US15/567,536 patent/US10316034B2/en active Active
-
2017
- 2017-08-24 IL IL254153A patent/IL254153A0/en unknown
-
2018
- 2018-07-19 HK HK18109398.9A patent/HK1249906A1/zh unknown
-
2021
- 2021-01-28 JP JP2021012044A patent/JP2021073256A/ja active Pending
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2012506368A (ja) * | 2008-09-16 | 2012-03-15 | プロキシマジェン エルティーディー | 新規化合物i |
Non-Patent Citations (6)
Title |
---|
JOURNAL OF PHARMACEUTICAL SCIENCES, vol. 66, no. 1, JPN6014023656, 1977, pages 1 - 19, ISSN: 0004904781 * |
PHARM TECH JAPAN, vol. 18, no. 10, JPN7014002019, 2002, pages 1629 - 1644, ISSN: 0004904783 * |
小嶌隆史: "医薬品開発における結晶性選択の効率化を目指して", 薬剤学, vol. 68, no. 5, JPN6009053757, 1 September 2008 (2008-09-01), pages 344 - 349, ISSN: 0004904784 * |
平山令明編, 有機化合物結晶作製ハンドブック −原理とノウハウ−, JPN6011053065, 25 July 2008 (2008-07-25), pages 57 - 84, ISSN: 0004904785 * |
長瀬博監訳, 最新 創薬化学 下巻, JPN6008054607, 25 September 1999 (1999-09-25), pages 347 - 365, ISSN: 0004904782 * |
高田則幸: "創薬段階における原薬Formスクリーニングと選択", PHARM STAGE, vol. 6, no. 10, JPN6009053755, 15 January 2007 (2007-01-15), pages 20 - 25, ISSN: 0004904786 * |
Also Published As
Publication number | Publication date |
---|---|
CN112851669A (zh) | 2021-05-28 |
SG11201707867WA (en) | 2017-11-29 |
GB201507031D0 (en) | 2015-06-10 |
KR20170139045A (ko) | 2017-12-18 |
HUE049985T2 (hu) | 2020-11-30 |
MX2017013049A (es) | 2017-12-08 |
EP3286190A1 (en) | 2018-02-28 |
WO2016170351A1 (en) | 2016-10-27 |
AU2016251707B2 (en) | 2020-02-20 |
EP3286190B1 (en) | 2020-06-03 |
DK3286190T3 (da) | 2020-07-13 |
HK1249906A1 (zh) | 2018-11-16 |
US10316034B2 (en) | 2019-06-11 |
IL254153A0 (en) | 2017-10-31 |
EA201792121A1 (ru) | 2018-03-30 |
ES2804155T3 (es) | 2021-02-04 |
PT3286190T (pt) | 2020-07-09 |
AR104360A1 (es) | 2017-07-12 |
US20180111928A1 (en) | 2018-04-26 |
AU2016251707A1 (en) | 2017-10-05 |
EA035668B1 (ru) | 2020-07-23 |
CN107531702A (zh) | 2018-01-02 |
CA2979144A1 (en) | 2016-10-27 |
JP2018513189A (ja) | 2018-05-24 |
BR112017020016A2 (pt) | 2018-06-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2021073256A (ja) | セミカルバジド感受性アミンオキシダーゼ(ssao)の阻害剤の医薬的塩形態 | |
US11040969B2 (en) | Compounds I | |
JP2022071072A (ja) | (s)-7-(1-アクリロイルピペリジン-4-イル)-2-(4-フェノキシフェニル)-4,5,6,7-テトラ-ヒドロピラゾロ[1,5-a]ピリミジン-3-カルボキサミドの結晶形、その調製、及びその使用 | |
EP3277688B1 (en) | Co-crystals of ibrutinib | |
JP2021073259A (ja) | セミカルバジド感受性アミンオキシダーゼ酵素阻害剤としての結晶性化合物 | |
EP3448846B1 (en) | Synthesis of indazoles | |
US11530208B2 (en) | Imidazo[4,5-C]pyridine derived SSAO inhibitors | |
JP2023024729A (ja) | ヤヌスキナーゼ阻害剤の結晶形 | |
CN116444529B (zh) | 一种氘代氮杂环丁烷类jak抑制剂及其用途 | |
US8859567B2 (en) | Hydrate of 1-{(2S)-2-amino-4-[2,4-bis(trifluoromethyl)-5,8-di-hydropyrido[3,4-D]pyrimidin-7(6H)-yl]-4-oxobutyl}-5,5-difluoro-piperidin-2-one tartrate | |
TW201710256A (zh) | 新穎醫藥鹽形態及結晶形態 | |
US11795168B2 (en) | Inhibiting cyclic amp-responsive element-binding protein (CREB) binding protein (CBP) | |
EP4230625A1 (en) | Crystal form of multi-substituted benzene ring compound maleate, and preparation method therefor and use thereof | |
WO2021190623A1 (zh) | Fgfr4抑制剂的盐型、晶型及其用途 | |
WO2023008470A1 (ja) | 縮環アミン誘導体 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20210226 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20210705 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20220120 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20220125 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20220425 |
|
A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A711 Effective date: 20220705 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20220705 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20220722 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20221025 |